BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Drake TM, Docherty AB, Harrison EM, Quint JK, Adamali H, Agnew S, Babu S, Barber CM, Barratt S, Bendstrup E, Bianchi S, Villegas DC, Chaudhuri N, Chua F, Coker R, Chang W, Crawshaw A, Crowley LE, Dosanjh D, Fiddler CA, Forrest IA, George PM, Gibbons MA, Groom K, Haney S, Hart SP, Heiden E, Henry M, Ho LP, Hoyles RK, Hutchinson J, Hurley K, Jones M, Jones S, Kokosi M, Kreuter M, MacKay LS, Mahendran S, Margaritopoulos G, Molina-Molina M, Molyneaux PL, O'Brien A, O'Reilly K, Packham A, Parfrey H, Poletti V, Porter JC, Renzoni E, Rivera-Ortega P, Russell AM, Saini G, Spencer LG, Stella GM, Stone H, Sturney S, Thickett D, Thillai M, Wallis T, Ward K, Wells AU, West A, Wickremasinghe M, Woodhead F, Hearson G, Howard L, Baillie JK, Openshaw PJM, Semple MG, Stewart I, Jenkins RG; ISARIC4C Investigators. Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. Am J Respir Crit Care Med 2020;202:1656-65. [PMID: 33007173 DOI: 10.1164/rccm.202007-2794OC] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 19.5] [Reference Citation Analysis]
Number Citing Articles
1 Basin S, Valentin S, Maurac A, Poussel M, Pequignot B, Brindel A, Poupet G, Robert C, Baumann C, Luc A, Soler J, Chabot F, Chaouat A. Progression to a severe form of COVID-19 among patients with chronic respiratory diseases. Respir Med Res 2021;81:100880. [PMID: 34974204 DOI: 10.1016/j.resmer.2021.100880] [Reference Citation Analysis]
2 Shen H, Zhang N, Liu Y, Yang X, He Y, Li Q, Shen X, Zhu Y, Yang Y. The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs. Front Pharmacol 2021;12:805535. [PMID: 35069217 DOI: 10.3389/fphar.2021.805535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 de Oliveira SM, Martins LVDO, Lupino-assad AP, Medeiros-ribeiro AC, de Moraes DA, Del-rio APT, Oliveira MC, Sampaio-barros PD, Kayser C. Severity and mortality of COVID-19 in patients with systemic sclerosis: a Brazilian multicenter study. Seminars in Arthritis and Rheumatism 2022. [DOI: 10.1016/j.semarthrit.2022.151987] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Goto Y, Sakamoto K, Fukihara J, Suzuki A, Omote N, Ando A, Shindo Y, Hashimoto N. COVID-19-Triggered Acute Exacerbation of IPF, an Underdiagnosed Clinical Entity With Two-Peaked Respiratory Failure: A Case Report and Literature Review. Front Med 2022;9:815924. [DOI: 10.3389/fmed.2022.815924] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lutchmansingh DD, Knauert MP, Antin-Ozerkis DE, Chupp G, Cohn L, Dela Cruz CS, Ferrante LE, Herzog EL, Koff J, Rochester CL, Ryu C, Singh I, Tickoo M, Winks V, Gulati M, Possick JD. A Clinic Blueprint for Post-Coronavirus Disease 2019 RECOVERY: Learning From the Past, Looking to the Future. Chest 2021;159:949-58. [PMID: 33159907 DOI: 10.1016/j.chest.2020.10.067] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
6 Li HH, Liu CC, Hsu TW, Lin JH, Hsu JW, Li AF, Yeh YC, Hung SC, Hsu HS. Upregulation of ACE2 and TMPRSS2 by particulate matter and idiopathic pulmonary fibrosis: a potential role in severe COVID-19. Part Fibre Toxicol 2021;18:11. [PMID: 33706759 DOI: 10.1186/s12989-021-00404-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Althuwaybi A, Al Quaimi M, Krishnan A, Jones R, Pearson J, Ward C. Hospitalization Outcomes for COVID-19 in Patients with Interstitial Lung Disease: A Potential Role for Aerodigestive Pathophysiology? Am J Respir Crit Care Med 2021;203:521-2. [PMID: 33217241 DOI: 10.1164/rccm.202010-4031LE] [Reference Citation Analysis]
8 Ntatsoulis K, Karampitsakos T, Tsitoura E, Stylianaki EA, Matralis AN, Tzouvelekis A, Antoniou K, Aidinis V. Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target. Front Immunol 2021;12:687397. [PMID: 34671341 DOI: 10.3389/fimmu.2021.687397] [Reference Citation Analysis]
9 Mena-Vázquez N, García-Studer A, Rojas-Gimenez M, Romero-Barco CM, Manrique-Arija S, Mucientes A, Velloso-Feijoo ML, Godoy-Navarrete FJ, Morales-Garrido P, Redondo-Rodríguez R, Ordoñez-Cañizares MC, Ortega-Castro R, Lisbona-Montañez JM, Hidalgo Conde A, Arnedo Díez de Los Ríos R, Cabrera César E, Espildora F, Aguilar-Hurtado MC, Añón-Oñate I, Ureña-Garnica I, Fernández-Nebro A. Importance of Vaccination against SARS-CoV-2 in Patients with Interstitial Lung Disease Associated with Systemic Autoimmune Disease. J Clin Med 2022;11:2437. [PMID: 35566564 DOI: 10.3390/jcm11092437] [Reference Citation Analysis]
10 Nakshbandi G, Moor CC, Johannson KA, Maher TM, Kreuter M, Wijsenbeek MS. Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era. ERJ Open Res 2021;7:00405-2021. [PMID: 34471631 DOI: 10.1183/23120541.00405-2021] [Reference Citation Analysis]
11 Yamaya T, Hagiwara E, Baba T, Iwasawa T, Ogura T. Outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs. Journal of Infection and Chemotherapy 2022. [DOI: 10.1016/j.jiac.2022.04.006] [Reference Citation Analysis]
12 Rinaldi S, Balsillie C, Truchon C, Al‐mubarak A, Mura M, Madill J. Nutrition implications of intrinsic restrictive lung disease. Nut in Clin Prac. [DOI: 10.1002/ncp.10849] [Reference Citation Analysis]
13 Velagacherla V, Suresh A, Mehta CH, Nayak UY. Advances and challenges in nintedanib drug delivery. Expert Opin Drug Deliv 2021;18:1687-706. [PMID: 34556001 DOI: 10.1080/17425247.2021.1985460] [Reference Citation Analysis]
14 Ferretti F, Cannatelli R, Benucci M, Carmagnola S, Clementi E, Danelli P, Dilillo D, Fiorina P, Galli M, Gallieni M, Genovese G, Giorgi V, Invernizzi A, Maconi G, Maier JA, Marzano AV, Morpurgo PS, Nebuloni M, Radovanovic D, Riva A, Rizzardini G, Sabiu G, Santus P, Staurenghi G, Zuccotti G, Sarzi-Puttini PC, Ardizzone S. How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group. Front Immunol 2021;12:656362. [PMID: 33936084 DOI: 10.3389/fimmu.2021.656362] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
15 Narayanamoorthy S, Pragathi S, Parthasarathy TN, Kalaiselvan S, Kureethara JV, Saraswathy R, Nithya P, Kang D. The COVID-19 Vaccine Preference for Youngsters Using PROMETHEE-II in the IFSS Environment. Symmetry 2021;13:1030. [DOI: 10.3390/sym13061030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Gallay L, Uzunhan Y, Borie R, Lazor R, Rigaud P, Marchand-Adam S, Hirschi S, Israel-Biet D, Valentin V, Cottin V. Risk Factors for Mortality after COVID-19 in Patients with Preexisting Interstitial Lung Disease. Am J Respir Crit Care Med 2021;203:245-9. [PMID: 33252997 DOI: 10.1164/rccm.202007-2638LE] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
17 Yamaya T, Hagiwara E, Baba T, Kitayama T, Murohashi K, Higa K, Sato Y, Otoshi R, Tabata E, Shintani R, Okabayashi H, Ikeda S, Niwa T, Nakazawa A, Oda T, Okuda R, Sekine A, Kitamura H, Komatsu S, Ogura T. Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019. Respir Investig 2021;59:596-601. [PMID: 33965361 DOI: 10.1016/j.resinv.2021.04.002] [Reference Citation Analysis]
18 Podolanczuk AJ, Richeldi L. COVID-19 and Interstitial Lung Disease: Keep Them Separate. Am J Respir Crit Care Med 2020;202:1614-6. [PMID: 33113338 DOI: 10.1164/rccm.202010-3918ED] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ray A, Chaudhry R, Rai S, Mitra S, Pradhan S, Sunder A, Nag DS. Prolonged Oxygen Therapy Post COVID-19 Infection: Factors Leading to the Risk of Poor Outcome. Cureus 2021;13:e13357. [PMID: 33633916 DOI: 10.7759/cureus.13357] [Reference Citation Analysis]
20 Hojo M, Terada-Hirashima J, Sugiyama H. COVID-19 and bronchial asthma: current perspectives. Glob Health Med 2021;3:67-72. [PMID: 33937568 DOI: 10.35772/ghm.2020.01117] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Gülsen A, König IR, Jappe U, Drömann D. Effect of comorbid pulmonary disease on the severity of COVID-19: A systematic review and meta-analysis. Respirology 2021;26:552-65. [PMID: 33955623 DOI: 10.1111/resp.14049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Bando T, Takei R, Mutoh Y, Sasano H, Yamano Y, Yokoyama T, Matsuda T, Kataoka K, Kimura T, Kondoh Y. Acute Exacerbation of Idiopathic Pulmonary Fibrosis after SARS-CoV-2 Vaccination. Eur Respir J 2022:2102806. [PMID: 35144990 DOI: 10.1183/13993003.02806-2021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
23 Nagase H, Nishimura Y, Matsumoto H, Sugimoto N, Iwanaga T, Sano A, Konno S, Hizawa N, Asano K, Horiguchi T, Yokoyama A; Japanese Respiratory Society, Scientific Assembly for Allergy, Immunology, and Inflammation. The prevalence of comorbid respiratory disease among COVID-19 patients, and mortality during the first wave in Japan: A nationwide survey by the Japanese Respiratory Society. Respir Investig 2021:S2212-5345(21)00117-9. [PMID: 34303646 DOI: 10.1016/j.resinv.2021.06.008] [Reference Citation Analysis]
24 Chiner-vives E, Cordovilla-pérez R, Rosa-carrillo DDL, García-clemente M, Izquierdo-alonso JL, Otero-candelera R, Llano LP, Sellares-torres J, Granda-orive JID. Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases. Archivos de Bronconeumología 2022. [DOI: 10.1016/j.arbres.2022.03.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Hong X, Wang L, Zhang K, Liu J, Liu J. Molecular Mechanisms of Alveolar Epithelial Stem Cell Senescence and Senescence-Associated Differentiation Disorders in Pulmonary Fibrosis. Cells 2022;11:877. [DOI: 10.3390/cells11050877] [Reference Citation Analysis]
26 Kent BD. Infectious disease in respiratory medicine. Breathe 2022;18:220022. [DOI: 10.1183/20734735.0022-2022] [Reference Citation Analysis]
27 Suarez-Cuartin G, Gasa M, Bermudo G, Ruiz Y, Hernandez-Argudo M, Marin A, Trias-Sabria P, Cordoba A, Cuevas E, Sarasate M, Ariza A, Sabater J, Romero N, Subirana C, Molina-Molina M, Santos S. Clinical Outcomes of Severe COVID-19 Patients Admitted to an Intermediate Respiratory Care Unit. Front Med (Lausanne) 2021;8:711027. [PMID: 34277674 DOI: 10.3389/fmed.2021.711027] [Reference Citation Analysis]
28 Mauro D, Ciancio A, Di Vico C, Passariello L, Rozza G, Pasquale MD, Pantano I, Cannistrà C, Bucci L, Scriffignano S, Riccio F, Patrone M, Scalise G, Ruscitti P, Montemurro MV, Giordano A, Vietri MT, Ciccia F. Serological Response to BNT162b2 Anti-SARS-CoV-2 Vaccination in Patients with Inflammatory Rheumatic Diseases: Results From the RHEUVAX Cohort. Front Immunol 2022;13:901055. [DOI: 10.3389/fimmu.2022.901055] [Reference Citation Analysis]
29 Villar-álvarez F, Martínez-garcía MÁ, Jiménez D, Fariñas-guerrero F, Ortiz de Lejarazu-leonardo R, López-campos JL, Blanco-aparicio M, Royo-crespo Í, García-ortega A, Trilla-garcía A, Trujillo-reyes JC, Fernández-prada M, Díaz-pérez D, Laporta-hernández R, Valenzuela C, Menéndez R, de la Rosa-carrillo D. Recomendaciones SEPAR sobre la vacuna COVID-19 en las enfermedades respiratorias. Open Respiratory Archives 2021;3:100097. [DOI: 10.1016/j.opresp.2021.100097] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Bocchino M, Lieto R, Romano F, Sica G, Bocchini G, Muto E, Capitelli L, Sequino D, Valente T, Fiorentino G, Rea G. Chest CT-based Assessment of 1-year Outcomes after Moderate COVID-19 Pneumonia. Radiology 2022;:220019. [PMID: 35536134 DOI: 10.1148/radiol.220019] [Reference Citation Analysis]
31 Ryan N, Meskell P. The experience of people with idiopathic pulmonary fibrosis living through the COVID-19 pandemic. J Adv Nurs 2022. [PMID: 35179243 DOI: 10.1111/jan.15187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Hara Y, Oshima Y, Tagami Y, Aoki A, Fujii H, Izawa A, Seki K, Kanai A, Yabe A, Watanabe K, Horita N, Kobayashi N, Kaneko T. Clinical importance of serum heme oxygenase-1 measurement in patients with acute exacerbation of idiopathic pulmonary fibrosis triggered by coronavirus disease 2019. Respiratory Medicine Case Reports 2022;36:101615. [DOI: 10.1016/j.rmcr.2022.101615] [Reference Citation Analysis]
33 Olschewski H, Eber E, Bucher B, Hackner K, Handzhiev S, Hoetzenecker K, Idzko M, Klepetko W, Kovacs G, Lamprecht B, Löffler-Ragg J, Meilinger M, Müller A, Prior C, Schindler O, Täubl H, Zacharasiewicz A, Zwick RH, Arns BM, Bolitschek J, Cima K, Gingrich E, Hochmair M, Horak F, Jaksch P, Kropfmüller R, Pfleger A, Puchner B, Puelacher C, Rodriguez P, Salzer HJF, Schenk P, Stelzmüller I, Strenger V, Urban M, Wagner M, Wimberger F, Flick H. Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022) : Updated statement of the Austrian Society of Pneumology (ASP). Wien Klin Wochenschr 2022. [PMID: 35449467 DOI: 10.1007/s00508-022-02018-x] [Reference Citation Analysis]
34 Naqvi SF, Lakhani DA, Sohail AH, Maurer J, Sofka S, Sarwari A, Hadi YB. Patients with idiopathic pulmonary fibrosis have poor clinical outcomes with COVID-19 disease: a propensity matched multicentre research network analysis. BMJ Open Respir Res 2021;8:e000969. [PMID: 34376400 DOI: 10.1136/bmjresp-2021-000969] [Reference Citation Analysis]
35 Boutin S, Hildebrand D, Boulant S, Kreuter M, Rüter J, Pallerla SR, Velavan TP, Nurjadi D. Host factors facilitating SARS-CoV-2 virus infection and replication in the lungs. Cell Mol Life Sci 2021;78:5953-76. [PMID: 34223911 DOI: 10.1007/s00018-021-03889-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Kittleson MM, Chambers DC, Cypel M, Potena L. Covid-19 in recipients of heart and lung transplantation: Learning from experience. J Heart Lung Transplant 2021;40:948-50. [PMID: 34246563 DOI: 10.1016/j.healun.2021.05.021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Ouyang L, Gong J, Yu M. Pre-existing interstitial lung disease in patients with coronavirus disease 2019: A meta-analysis. Int Immunopharmacol 2021;100:108145. [PMID: 34547678 DOI: 10.1016/j.intimp.2021.108145] [Reference Citation Analysis]
38 Marcon A, Schievano E, Fedeli U. Mortality Associated with Idiopathic Pulmonary Fibrosis in Northeastern Italy, 2008-2020: A Multiple Cause of Death Analysis. Int J Environ Res Public Health 2021;18:7249. [PMID: 34299699 DOI: 10.3390/ijerph18147249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Lee KS, Wi YM. Residual Lung Lesions at 1-year CT after COVID-19. Radiology 2021;:212350. [PMID: 34609154 DOI: 10.1148/radiol.2021212350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 McCarthy C, Keane MP. Contemporary Concise Review 2021: Interstitial lung disease. Respirology 2022. [PMID: 35513341 DOI: 10.1111/resp.14278] [Reference Citation Analysis]
41 Udwadia ZF, Koul PA, Dhooria S. The impact of COVID-19 on patients with preexisting interstitial lung disease: High mortality in these high-risk patients. Lung India 2021;38:S1-3. [PMID: 33686971 DOI: 10.4103/lungindia.lungindia_60_21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Granata S, Carratù P, Stallone G, Zaza G. mTOR-Inhibition and COVID-19 in Kidney Transplant Recipients: Focus on Pulmonary Fibrosis. Front Pharmacol 2021;12:710543. [PMID: 34497515 DOI: 10.3389/fphar.2021.710543] [Reference Citation Analysis]
43 Lee H, Choi H, Yang B, Lee SK, Park TS, Park DW, Moon JY, Kim TH, Sohn JW, Yoon HJ, Kim SH. Interstitial lung disease increases susceptibility to and severity of COVID-19. Eur Respir J 2021:2004125. [PMID: 33888524 DOI: 10.1183/13993003.04125-2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Aveyard P, Gao M, Lindson N, Hartmann-Boyce J, Watkinson P, Young D, Coupland CAC, Tan PS, Clift AK, Harrison D, Gould DW, Pavord ID, Hippisley-Cox J. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. Lancet Respir Med 2021;9:909-23. [PMID: 33812494 DOI: 10.1016/S2213-2600(21)00095-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
45 Beltramo G, Cottenet J, Mariet AS, Georges M, Piroth L, Tubert-Bitter P, Bonniaud P, Quantin C. Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study. Eur Respir J 2021:2004474. [PMID: 34016619 DOI: 10.1183/13993003.04474-2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
46 Lommatzsch M, Rabe KF, Taube C, Joest M, Kreuter M, Wirtz H, Blum TG, Kolditz M, Geerdes-Fenge H, Otto-Knapp R, Häcker B, Schaberg T, Ringshausen FC, Vogelmeier CF, Reinmuth N, Reck M, Gottlieb J, Konstantinides S, Meyer FJ, Worth H, Windisch W, Welte T, Bauer T. [Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)]. Pneumologie 2021;75:19-30. [PMID: 33242887 DOI: 10.1055/a-1321-3400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
47 Boutou AK, Asimakos A, Kortianou E, Vogiatzis I, Tzouvelekis A. Long COVID-19 Pulmonary Sequelae and Management Considerations. J Pers Med 2021;11:838. [PMID: 34575615 DOI: 10.3390/jpm11090838] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Chaudhuri N, George PM, Kreuter M, Molina-Molina M, Rivera-Ortega P, Stella GM, Stewart I, Spencer LG, Wells AU, Jenkins RG. Reply to Althuwaybi et al.: Hospitalization Outcomes for COVID-19 in Patients with Interstitial Lung Disease: A Potential Role for Aerodigestive Pathophysiology? Am J Respir Crit Care Med 2021;203:522-4. [PMID: 33217244 DOI: 10.1164/rccm.202011-4146LE] [Reference Citation Analysis]
49 Maze MJ. Chronic pulmonary comorbidities increase the risk of severe COVID-19, but critical details remain undetermined. Respirology 2021;26:520-1. [PMID: 33955114 DOI: 10.1111/resp.14067] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Cilli A, Hanta I, Uzer F, Coskun F, Sevinc C, Deniz PP, Parlak M, Altunok E, Tertemiz KC, Ursavas A. Characteristics and outcomes of COVID-19 patients with IPF: a multi-center retrospective study. Respiratory Medicine and Research 2022. [DOI: 10.1016/j.resmer.2022.100900] [Reference Citation Analysis]
51 Valenzuela C, Waterer G, Raghu G. Interstitial lung disease before and after COVID-19: a double threat? Eur Respir J 2021;58:2101956. [PMID: 34857587 DOI: 10.1183/13993003.01956-2021] [Reference Citation Analysis]
52 Uemasu K, Yasuda Y, Hirayama Y, Arasawa S, Iwashima D, Takahashi KI. Post-COVID-19 interstitial lung disease presenting with profound hypoxemia: Report of three cases demonstrating a good response to high-dose corticosteroid therapy. J Infect Chemother 2021:S1341-321X(21)00321-4. [PMID: 34810106 DOI: 10.1016/j.jiac.2021.11.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Nikitopoulou I, Fanidis D, Ntatsoulis K, Moulos P, Mpekoulis G, Evangelidou M, Vassiliou AG, Dimakopoulou V, Jahaj E, Tsipilis S, Orfanos SE, Dimopoulou I, Angelakis E, Akinosoglou K, Vassilaki N, Tzouvelekis A, Kotanidou A, Aidinis V. Increased Autotaxin Levels in Severe COVID-19, Correlating with IL-6 Levels, Endothelial Dysfunction Biomarkers, and Impaired Functions of Dendritic Cells. Int J Mol Sci 2021;22:10006. [PMID: 34576169 DOI: 10.3390/ijms221810006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Earl N, Schoeneberg D, Davidson PD. Severe progression of idiopathic pulmonary fibrosis post-COVID-19 infection. BMJ Case Rep 2021;14:e244472. [PMID: 34667037 DOI: 10.1136/bcr-2021-244472] [Reference Citation Analysis]
55 Myall KJ, Martinovic JL, West A. How COVID-19 interacts with interstitial lung disease. Breathe 2022;18:210158. [DOI: 10.1183/20734735.0158-2021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Cottin V, Bonniaud P, Cadranel J, Crestani B, Jouneau S, Marchand-Adam S, Nunes H, Wémeau-Stervinou L, Bergot E, Blanchard E, Borie R, Bourdin A, Chenivesse C, Clément A, Gomez E, Gondouin A, Hirschi S, Lebargy F, Marquette CH, Montani D, Prévot G, Quetant S, Reynaud-Gaubert M, Salaun M, Sanchez O, Trumbic B, Berkani K, Brillet PY, Campana M, Chalabreysse L, Chatté G, Debieuvre D, Ferretti G, Fourrier JM, Just N, Kambouchner M, Legrand B, Le Guillou F, Lhuillier JP, Mehdaoui A, Naccache JM, Paganon C, Rémy-Jardin M, Si-Mohamed S, Terrioux P; OrphaLung. [French practical guidelines for the diagnosis and management of IPF - 2021 update, full version]. Rev Mal Respir 2022:S0761-8425(22)00035-3. [PMID: 35752506 DOI: 10.1016/j.rmr.2022.01.014] [Reference Citation Analysis]
57 Thomas M, Price OJ, Hull JH. Pulmonary function and COVID-19. Curr Opin Physiol 2021;21:29-35. [PMID: 33817453 DOI: 10.1016/j.cophys.2021.03.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]